Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma.

Marigdalia K Ramirez-FortB Meier-SchiesserK LachanceS S MahaseC D ChurchMuhammad Junaid NiazH LiuV NavarroA NikolopoulouD V KazakovE ContassotD P NguyenJ SachL HadravskyY ShengS T TagawaX WuC S LangeL E FrenchP T NghiemN H Bander

Published in: Skin health and disease (2020)

We report the first evidence of prevalent FOLH1 expression within MCC-associated neo-vessels, in 60-77% of patients in a large MCC cohort. Given this data, and the need for alternatives to immune therapies it is appropriate to explore the safety and efficacy o f FOLH1-targeted brachytherapy for MCC.

Keyphrases

high dose
end stage renal disease
radiation therapy
newly diagnosed
chronic kidney disease
poor prognosis
ejection fraction
prognostic factors
peritoneal dialysis
machine learning
squamous cell carcinoma
low dose
cancer therapy
big data
deep learning